摘要
目的:探讨帕拉米韦及沙丁胺醇吸入治疗小儿病毒性肺炎的效果及对神经氨酸酶水平的影响。方法:选择2015年2月-2020年12月在辽阳市第二人民医院诊治的小儿病毒性肺炎患儿128例作为研究对象。根据随机信封抽签原则将患儿分为联合组与对照组,每组64例。对照组给予帕拉米韦治疗,联合组给予帕拉米韦及沙丁胺醇吸入治疗,两组均治疗7 d。比较两组疗效、主要症状缓解时间、治疗期间不良反应发生情况及治疗前后神经氨酸酶(NA)水平。结果:联合组治疗总有效率为98.4%,高于对照组89.1%(P<0.05)。联合组发热、咳嗽、咽喉痛缓解时间均短于对照组(P<0.05)。两组治疗期间腹泻、恶心、腹痛发生率比较,差异均无统计学意义(P>0.05)。治疗后,两组血清NA水平均低于治疗前,且联合组低于对照组,差异均有统计学意义(P<0.05)。结论:帕拉米韦及沙丁胺醇吸入治疗小儿病毒性肺炎能促进缓解临床症状,提高疗效,抑制血清NA的释放,且不会增加不良反应的发生。
Objective:To explore the efficacy of Peramivir and Salbutamol Inhalation in the treatment of children with viral pneumonia and the influence on the level of neuraminidase (NA).Method:From February 2015 to December 2020,128 children with viral pneumonia diagnosed and treated in the Second People’s Hospital of Liaoyang were selected as the research objects.All children were divided into the combination group and the control group accorded to the principle of random envelope drawing,64 children in each group.The control group was treated with Peramivir,and the combination group was treated with Peramivir and Salbutamol Inhalation,two groups were treated for 7 d.The curative effect,the time to relieve the main symptoms,the occurrence of adverse reactions during treatment and the NA level before and after treatment were compared between two groups.Result:The total effective rates of treatment in the combination group was 98.4%,which was higher than 89.1% in the control group (P<0.05).The relief times of fever,cough and sore throat in the combination group were shorter than those in the control group (P<0.05).The main adverse reactions during the treatment period of the two groups were diarrhea,nausea and abdominal pain,there were no statistically significant differences in the incidence of adverse reactions between two groups (P>0.05).After treatment,the serum NA levels of two groups were lower than those before treatment,and the combination group was lower than that of the control group,the differences were statistically significant (P<0.05).Conclusion:Peramivir and Salbutamol inhalation in the treatment of infant influenza virus-associated pneumonia can promote the alleviation of clinical symptoms,improve the efficacy,inhibit the release of serum NA,and it will not increase the occurrence of adverse reactions.
作者
杨文旭
YANG Wenxu(The Second People’s Hospital of Liaoyang,Liaoning Province,Liaoyang 111000,China)
出处
《中国医学创新》
CAS
2022年第11期62-65,共4页
Medical Innovation of China
